Investigating SCR-6920 Capsule for Patients with Advanced Malignant Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, open-label, multi-center study aims to evaluate the safety and tolerability of SCR-6920 capsules in patients with advanced malignant tumors, including solid tumors and relapsed/refractory non-Hodgkin lymphoma. The study will involve a dose escalation approach to identify the maximum tolerated dose and the recommended Phase 2 dose. Participants will be monitored for pharmacokinetics and preliminary efficacy to assess the treatment's potential benefits. The study is designed for patients who have not responded to standard therapies or for whom such therapies are not suitable.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL
* Relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available.
* At least one evaluable or measurable lesion (as defined in the protocol).
* ECOG Performance Status 0 or 1.
* Life expectancy ≥12 weeks.
* Adequate organ function (as defined in the protocol).
* Reproductive criteria (as defined in the protocol).

Exclusion Criteria:

* Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption.
* Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
* Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
* Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose.
* History of a second malignancy within 2 years (as defined in the protocol).
* Active uncontrolled or symptomatic lung disease (as defined in the protocol).
* Intracranial hypertension or active uncontrolled or symptomatic CNS metastases.
* Known or suspected hypersensitivity to study medications.
* Known active uncontrolled or symptomatic CNS metastases.
* The investigator determined that the patient should not participate in the study.
* Known mental illness or substance abuse that may disrupt therapy.
* Clinically significant cardiac abnormalities (as defined in the protocol).
* Gestating or Lactating women.
* Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose.
* The patient is currently using a drug known to be a strong inhibitor or inducer of CYP3A4.

Where it's running

• Shandong Cancer Hospital
  Jinan, Shandong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SB-4826 for adults with advanced solid tumors or non-Hodgkin lymphoma

  This trial tests whether the oral drug SB-4826, given alone or with rituximab, is safe and can help adults with advanced solid tumors or non-Hodgkin lymphoma.

  Recruiting Phase 1/2 University of California, San Diego · La Jolla, California · NCT07222631

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors

  This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07776899

• Intrathecal Cytarabine and Hydrocortisone to Treat ICANS in NHL Patients Receiving CAR-T

  This trial tests whether giving cytarabine and hydrocortisone into the spine early after CAR-T therapy can reduce brain-related side effects in adults with non-Hodgkin lymphoma.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07763210

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.